vs
Side-by-side financial comparison of Invesco Mortgage Capital Inc. (IVR) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Invesco Mortgage Capital Inc. is the larger business by last-quarter revenue ($21.3M vs $20.6M, roughly 1.0× Entrada Therapeutics, Inc.). Invesco Mortgage Capital Inc. runs the higher net margin — 242.2% vs -84.4%, a 326.6% gap on every dollar of revenue. On growth, Invesco Mortgage Capital Inc. posted the faster year-over-year revenue change (55.4% vs -65.2%). Over the past eight quarters, Invesco Mortgage Capital Inc.'s revenue compounded faster (74.2% CAGR vs 6.4%).
Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
IVR vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.3M | $20.6M |
| Net Profit | $51.5M | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | — | -106.0% |
| Net Margin | 242.2% | -84.4% |
| Revenue YoY | 55.4% | -65.2% |
| Net Profit YoY | 1368.7% | -173.8% |
| EPS (diluted) | $0.72 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.3M | — | ||
| Q3 25 | $17.6M | — | ||
| Q2 25 | $17.7M | — | ||
| Q1 25 | $18.8M | $20.6M | ||
| Q4 24 | $13.7M | $37.4M | ||
| Q3 24 | $7.5M | $19.6M | ||
| Q2 24 | $8.6M | $94.7M | ||
| Q1 24 | $7.0M | $59.1M |
| Q4 25 | $51.5M | — | ||
| Q3 25 | $53.5M | — | ||
| Q2 25 | $-23.3M | — | ||
| Q1 25 | $19.6M | $-17.3M | ||
| Q4 24 | $3.5M | $1.1M | ||
| Q3 24 | $40.7M | $-14.0M | ||
| Q2 24 | $-13.5M | $55.0M | ||
| Q1 24 | $29.1M | $23.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -106.0% | ||
| Q4 24 | — | -15.7% | ||
| Q3 24 | — | -110.7% | ||
| Q2 24 | — | 56.4% | ||
| Q1 24 | — | 35.7% |
| Q4 25 | 242.2% | — | ||
| Q3 25 | 303.6% | — | ||
| Q2 25 | -131.6% | — | ||
| Q1 25 | 104.4% | -84.4% | ||
| Q4 24 | 25.6% | 3.0% | ||
| Q3 24 | 542.2% | -71.7% | ||
| Q2 24 | -155.9% | 58.1% | ||
| Q1 24 | 415.9% | 39.7% |
| Q4 25 | $0.72 | — | ||
| Q3 25 | $0.74 | — | ||
| Q2 25 | $-0.40 | — | ||
| Q1 25 | $0.26 | $-0.42 | ||
| Q4 24 | $-0.09 | $-0.20 | ||
| Q3 24 | $0.63 | $-0.35 | ||
| Q2 24 | $-0.38 | $1.55 | ||
| Q1 24 | $0.49 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $56.0M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $797.5M | $417.3M |
| Total Assets | $6.5B | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $56.0M | — | ||
| Q3 25 | $58.5M | — | ||
| Q2 25 | $59.4M | — | ||
| Q1 25 | $42.9M | $67.8M | ||
| Q4 24 | $73.4M | $101.2M | ||
| Q3 24 | $48.3M | $78.0M | ||
| Q2 24 | $58.8M | $185.3M | ||
| Q1 24 | $59.9M | $68.4M |
| Q4 25 | $797.5M | — | ||
| Q3 25 | $769.6M | — | ||
| Q2 25 | $709.4M | — | ||
| Q1 25 | $759.2M | $417.3M | ||
| Q4 24 | $730.7M | $428.7M | ||
| Q3 24 | $857.0M | $422.4M | ||
| Q2 24 | $759.2M | $429.9M | ||
| Q1 24 | $785.6M | $269.4M |
| Q4 25 | $6.5B | — | ||
| Q3 25 | $6.0B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $6.2B | $486.5M | ||
| Q4 24 | $5.7B | $526.3M | ||
| Q3 24 | $6.1B | $554.6M | ||
| Q2 24 | $5.1B | $582.0M | ||
| Q1 24 | $5.2B | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $157.1M | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | 3.05× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $157.1M | — | ||
| Q3 25 | $37.3M | — | ||
| Q2 25 | $40.6M | — | ||
| Q1 25 | $19.3M | $-38.5M | ||
| Q4 24 | $183.2M | $-31.6M | ||
| Q3 24 | $30.8M | $-24.3M | ||
| Q2 24 | $33.0M | $39.8M | ||
| Q1 24 | $57.5M | $-25.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-39.7M | ||
| Q4 24 | — | $-32.2M | ||
| Q3 24 | — | $-24.9M | ||
| Q2 24 | — | $38.8M | ||
| Q1 24 | — | $-26.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -192.9% | ||
| Q4 24 | — | -86.2% | ||
| Q3 24 | — | -127.3% | ||
| Q2 24 | — | 41.0% | ||
| Q1 24 | — | -44.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.6% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | 3.05× | — | ||
| Q3 25 | 0.70× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 52.24× | -27.94× | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | 1.97× | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
